AAPG AAPG
Company Profile ↓Company Overview
AAPG (AAPG) is a publicly traded company listed on with a market capitalization of $6.29B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 39.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $574.12M (-41.5% YoY); net profit $-1.24B.
- Trailing 12 Months Year-on-year growth — revenue -41.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 39.9%, profit CAGR -13.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.89% |
| 1 Year: | -41.46% |
Compounded Profit Growth
| 5 Years: | -13.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -60.51% |
| 6 Months: | -27.75% |
| 3 Months: | -23.04% |
| 1 Month: | -9.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 39.9% over 5 years.
CONS
- Earnings shrank at -13.6% CAGR over 5 years.
- Trading 64.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 209.71M | 221.98M | 980.65M | 574.12M |
| Cost of Revenue | - | 22.00M | 30.54M | 29.09M | 48.94M |
| Gross Profit | - | 187.71M | 191.44M | 951.57M | 525.18M |
| Operating Expenses | - | 1.04B | 1.06B | 1.32B | 1.72B |
| Operating Income | - | -849.81M | -872.64M | -369.73M | -1.20B |
| EBITDA | - | -771.47M | -743.61M | -237.63M | -1.10B |
| Interest Expense | - | 52.78M | 96.06M | 64.45M | 54.07M |
| Pretax Income | - | -887.17M | -932.86M | -395.25M | -1.24B |
| Tax Provision | - | -4.25M | -7.15M | 10.43M | 6.94M |
| Net Income | - | -882.92M | -925.64M | -405.43M | -1.24B |
| Diluted EPS | -12.28 | -13.40 | -13.12 | -5.36 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.83B | 2.50B | 2.62B | 3.96B |
| Current Assets | - | 1.64B | 1.34B | 1.47B | 2.94B |
| Cash & Equivalents | - | 1.48B | 1.07B | 1.24B | 2.46B |
| Inventory | - | 9.45M | 16.17M | 6.60M | 28.62M |
| Receivables | - | 54.36M | 145.89M | 83.14M | 252.94M |
| Total Liabilities | - | 2.42B | 2.43B | 2.34B | 2.63B |
| Current Liabilities | - | 881.15M | 934.17M | 1.17B | 1.64B |
| Long Term Debt | - | 1.27B | 1.17B | 868.64M | 742.33M |
| Total Debt | - | 1.79B | 1.80B | 1.67B | 1.98B |
| Total Equity | - | 408.66M | 60.42M | 264.19M | 1.32B |
| Shares Outstanding | - | 265.19M | 290.20M | 315.22M | 373.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -653.91M | -726.08M | -111.36M | -1.17B |
| Investing Cash Flow | - | -384.61M | 21.92M | -362.04M | -1.00B |
| Financing Cash Flow | - | 619.27M | 368.75M | 314.77M | 2.54B |
| Capital Expenditure | - | -236.96M | -56.84M | -24.29M | -27.57M |
| Free Cash Flow | - | -890.88M | -782.92M | -135.65M | -1.20B |
| Net Change in Cash | - | -419.26M | -335.40M | -158.62M | 365.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 89.5% | 86.2% | 97.0% | 91.5% |
| Operating Margin % | - | -405.2% | -393.1% | -37.7% | -208.6% |
| Net Margin % | - | -421.0% | -417.0% | -41.3% | -216.5% |
| ROE % | - | -216.1% | -1,532.1% | -153.5% | -93.8% |
| ROCE % | - | -43.6% | -55.7% | -25.5% | -51.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | 0.02% | 16.06K | $270.62K |
| 2 | XY Capital Ltd | 0.01% | 13.01K | $219.35K |
| 3 | UBS Group AG | - | 124 | $2.09K |
| 4 | Tower Research Capital LLC (TRC) | - | 518 | $8.73K |
| 5 | Royal Bank of Canada | - | 6 | $101 |
| 6 | Morgan Stanley | - | 498 | $8.39K |
| 7 | Eversource Wealth Advisors, Llc | - | 24 | $404 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AAPG
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855),please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on A…
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discove…
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Appointments put dedicated leadership behind two separate priorities: building Ascentage Pharma’s own commercial organization in the United States, and expanding its global business development programROCKVILLE, Md., Aug. 02, 2026 (GLOBE NE…
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 160.1% in Ascentage Pharma Group International - Unsponsored ADR (AAPG). While the effectiveness of this highly sought-after metric is questionable, th…
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and …
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group International - Unsponsored ADR (AAPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e…
AAPG — Frequently Asked Questions
What is the current share price of AAPG?
As of 2026-08-05 17:25 PDT, AAPG trades at $16.86 on NASDAQ/NYSE. Its 52-week range is $16.69 to $47.90.
What is the market capitalisation of AAPG?
AAPG has a market capitalisation of $6.29B on NASDAQ/NYSE.
What is the P/E ratio of AAPG?
AAPG trades at a trailing price-to-earnings (P/E) ratio of -3.15. Its price-to-book (P/B) ratio is 4.75.
What is the return on equity (ROE) of AAPG?
AAPG has a return on equity (ROE) of -93.83%. Its return on capital employed (ROCE) is -50.94%.
Is AAPG a good stock to buy?
This page provides a data-driven analysis of AAPG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.